aibio
Distress ·
Atea Pharmaceuticals authorizes $25 million buyback, reaches agreement with Radoff-JEC Group
The Radoff-JEC Group withdrew its director slate under the agreement. Atea's review of strategic alternatives with Evercore is still going.
AVIR Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals (AVIR) news AVIR buyback news
Latest Atea Pharmaceuticals news
We have not published a story on Atea Pharmaceuticals yet. When there is news, it will appear here.
Atea Pharmaceuticals annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $148.0 million | $144.1 million |
| Net income (loss) | -$158.3 million | -$168.4 million |
| Cash from operations | -$132.0 million | -$135.5 million |
| Cash and equivalents | $95.7 million | $64.7 million |
| Short-term investments | $206.1 million | $390.0 million |
Questions about Atea Pharmaceuticals
Does Atea Pharmaceuticals have a share buyback?
Our latest story on this, dated Apr 17, 2025: "Atea Pharmaceuticals authorizes $25 million buyback, reaches agreement with Radoff-JEC Group". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Atea Pharmaceuticals?
Atea Pharmaceuticals, Inc. trades under the ticker AVIR on NASDAQ.
Where is Atea Pharmaceuticals listed?
Atea Pharmaceuticals, Inc. is listed on NASDAQ.
What is the SEC CIK of Atea Pharmaceuticals?
The SEC Central Index Key (CIK) for Atea Pharmaceuticals, Inc. is 1593899. Its filings are on SEC EDGAR.
How many shares does Atea Pharmaceuticals have outstanding?
80,204,699 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12.
Which country or territory is Atea Pharmaceuticals listed under?
Our directory records Atea Pharmaceuticals, Inc. under United States.
What does Atea Pharmaceuticals do?
Our directory classifies Atea Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Atea Pharmaceuticals?
The ISIN recorded for Atea Pharmaceuticals, Inc. is US04683R1068.
Does aibio.space cover Atea Pharmaceuticals?
aibio.space lists Atea Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Atea Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as MA.
Is Atea Pharmaceuticals profitable?
Atea Pharmaceuticals, Inc. reported a net loss of $158.3 million for the fiscal year ended Dec 31, 2025, and used $132.0 million of cash in operations, per its annual report to the SEC.
How much does Atea Pharmaceuticals spend on research and development?
$148.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Atea Pharmaceuticals have?
$219.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Atea Pharmaceuticals (AVIR) stock news?
Our latest story on Atea Pharmaceuticals, dated Apr 17, 2025: "Atea Pharmaceuticals authorizes $25 million buyback, reaches agreement with Radoff-JEC Group". The Radoff-JEC Group withdrew its director slate under the agreement. Atea's review of strategic alternatives with Evercore is still going. Source.
Is Atea Pharmaceuticals in financial distress?
Our latest distress story, dated Apr 17, 2025: "Atea Pharmaceuticals authorizes $25 million buyback, reaches agreement with Radoff-JEC Group". The Radoff-JEC Group withdrew its director slate under the agreement. Atea's review of strategic alternatives with Evercore is still going. Source.
Investor discussion: Atea Pharmaceuticals
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- Atea Pharmaceuticals, Inc.
- CIK
- 1593899
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- AVIR (Nasdaq)
- State or country of incorporation
- MA
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 225 FRANKLIN STREET, BOSTON, MA, 02110
- Phone
- (857) 284-8891
- Shares outstanding
- 80,204,699 as of 2026-08-10 (10-Q filed 2026-08-12)
Recent filings
Listing details
- Company
- Atea Pharmaceuticals, Inc.
- Ticker
- AVIR
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US04683R1068
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction